

**Final Appraisal Recommendation**

Advice No: 1314 – June 2014

**Eltrombopag (as olamine) (Revolade®)  
25 mg and 50 mg film-coated tablets**

**Submission by Novartis Pharmaceuticals UK Ltd**

**Recommendation of AWMSG**

**Eltrombopag (Revolade®) is recommended for use within NHS Wales in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.**

**Additional notes:**

- Treatment with eltrombopag should be initiated only by physicians experienced in the management of advanced HCV, and only when the risks of thrombocytopenia or withholding antiviral therapy necessitate intervention. If treatment is considered clinically indicated, close monitoring of these patients is required.
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 607), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	GlaxoSmithKline
Date of first issue	June 2014
Last reviewed	September 2017



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1314:  
eltrombopag (Revolade®) 25 mg and 50 mg film-coated tablets. June 2014.

